Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SACT 1

Next Previous
Drug Profile

SACT 1

Alternative Names: SACT-1

Latest Information Update: 22 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aptorum Group
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cell death stimulants; N-myc proto-oncogene protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Neuroblastoma
  • Preclinical Cancer
  • No development reported Colorectal cancer; Triple negative breast cancer

Most Recent Events

  • 22 May 2026 Aptorum Group announces intention to submit NDA for Neuroblastoma and other potential cancer types in 2032
  • 22 May 2026 Aptorum Group plans a phase II/III trial for Neuroblastoma and other potential cancer types in 2032
  • 31 Dec 2025 Aptorum Group receives CTA and IND approvals for ALS 4 form Health Canada and US FDA to commence a human clinical trial

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top